All In Biotech

Drug Trial Radar · NCT07012148

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

FORESITE (FOREcasting Seizures to Initiate ThErapy): Optimizing Management of Drug-Resistant Epilepsy Using Seizure Forecasts Via Subscalp EEG and Wearables

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Mayo Clinic is conducting a research study to test a new approach to managing seizures in people with epilepsy whose seizures have not been fully controlled with regular medications. The study uses a small sensor placed just under the skin (not inside the brain) that continuously records electrical brain activity. This information is used to train a personalized computer algorithm that learns your individual seizure patterns and forecasts when a seizure is more likely to occur. If you are eligible and choose to participate, you would receive advance warning of elevated seizure risk, allowing you to take a fast-acting medication before a seizure happens. This medication would be in addition to the regular medicines prescribed by your doctor. The goal of the study is to understand whether this kind of forecasting system is safe, comfortable to live with, and capable of helping people gain more control over their seizures with a minimum amount of additional medication. Participation involves a minor surgical procedure to implant a small electrode under the skin above your ear that records your brain's electrical signals continuously over time. You would also wear a smart watch during the study. For the first six months, the system collects data to personalize your seizure forecast model and would not give you an alert. In the second six months, we would calculate your daily seizure risk and you would receive alerts on days when your risk is elevated. On these higher seizure risk days you would take a prescribed fast-acting nasal spray medication. The study is open to adults who continue to have 2 or more seizures per month in spite of having tried at least two antiseizure medications in the past, and whose seizures have shown involvement of the temporal lobe. All study-related procedures, devices, and study medication are provided at no cost to participants. Participants receive financial compensation for their time, and travel expenses to and from Mayo Clinic Rochester are reimbursed for anyone traveling more than 100 miles. If you are interested in learning more, please contact our research coordinator by email at Laivell.Jeffrey@mayo.edu.

Conditions

  • Focal Epilepsy
  • Generalized Seizure
  • Drug Refractory Epilepsy

Interventions

  • UNEEG SubQ device, seizure forecasts, nasal diazepamDevice

    Subjects will be implanted with the UNEEG SubQ device in the neurosurgical operating suite. Electrodes will be placed over the temporal lobe of the hemisphere established as the origin of seizures by previous EEG monitoring. Only one UNEEG device will be placed, and only the seizure onset hemisphere will be covered. Subjects will have individualized seizure forecast models created, and will take a supplemental antiseizure medicine during periods of elevated seizure risk.

  • Preventative Medication (PM)Drug

    Subjects will take nasal diazepam in response to pre-seizure alerts to evaluate the potential for this medication to prevent seizures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Adverse EventsTime frame: 12 months
  2. Safety- cardiorespiratory eventsTime frame: 12 months
  3. Feasibility outcomeTime frame: 12 months
  4. Preseizure alert feasibilityTime frame: 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.